Efficacy and safety of second-generation CAR T-cell therapy in diffuse large B-cell lymphoma: A meta-analysis

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2-3 years following immunochemotherapy, 30-40% of patients will experience a relapse or a refractory disease, thereby exhibiting a poor prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Mansour, Mubarak, Al-Foheidi, Meteb, Ibrahim, Ezzeldin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416618/
https://www.ncbi.nlm.nih.gov/pubmed/32789017
http://dx.doi.org/10.3892/mco.2020.2103

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416618/
https://www.ncbi.nlm.nih.gov/pubmed/32789017
http://dx.doi.org/10.3892/mco.2020.2103

Ejemplares similares